NEW DATA SHOW ORAL FERRIC MALTOL (FERACCRU®) MAY BE A COST-EFFECTIVE ALTERNATIVE TO INTRAVENOUS (IV) CARBOXYMALTOSE WITH AT LEAST AS GREAT BENEFITS IN THE QUALITY OF LIFE OF PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INFLAMMATORY BOWEL DISEASE (IBD)
19 February 2020
NORGINE B.V. ENTERS INTO EXCLUSIVE LICENCE AND DISTRIBUTION AGREEMENTS FOR THE COMMERCIALISATION OF PLENVU® IN A NUMBER OF COUNTRIES IN LATIN AMERICA, SOUTHERN AFRICA, CENTRAL AND EASTERN EUROPE
12 February 2020
The Norgine business code has been adopted by all legal entities within the Norgine Group and is available in seven languages.
The Norgine business code establishes the framework for achieving Norgine’s vision to deliver innovative medicines for the benefit of patients, employees and other stakeholders. As we endeavour to achieve our vision, we must do so through the application of consistently high standards of ethical conduct.
From its inception, the Norgine business code was established based on a broad consultation process across the Norgine Group and a comprehensive consideration of all the activities of the Company.
The core principles of One Norgine, Innovation and Trustworthiness underpin all of our activities, which together with our focus upon continuous improvements in quality are fundamental to achieving our vision. The Norgine business code will continue to evolve, but it will always embody best practice in the industry and the distinctive characteristics of Norgine’s employees and partners.